Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Has Average Price Target of $18.12 According to Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average recommendation of “Buy” from the nine research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $18.12.

LXEO has been the subject of a number of recent analyst reports. Leerink Partners reaffirmed an “outperform” rating and set a $15.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, September 23rd. Wall Street Zen raised shares of Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. JPMorgan Chase & Co. cut their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Lexeo Therapeutics in a research note on Tuesday, September 22nd. Finally, Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Lexeo Therapeutics in the 2nd quarter valued at about $26,717,000. Montanova Capital LLC grew its holdings in shares of Lexeo Therapeutics by 410.7% during the second quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock worth $29,718,000 after purchasing an additional 5,134,200 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Lexeo Therapeutics in the second quarter worth approximately $18,409,000. Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $32,769,000. Finally, Affinity Asset Advisors LLC raised its stake in Lexeo Therapeutics by 57.8% in the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock valued at $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $3.41 on Tuesday. Lexeo Therapeutics has a one year low of $2.98 and a one year high of $10.99. The business has a fifty day moving average price of $4.41 and a 200-day moving average price of $4.97. The firm has a market capitalization of $279.78 million, a P/E ratio of -2.97 and a beta of 1.63.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). Sell-side analysts expect that Lexeo Therapeutics will post -1.18 earnings per share for the current fiscal year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc (NASDAQ:LXEO) is a clinical-stage biotechnology company developing genetic medicines for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other gene therapy technologies to deliver genetic material intended to address underlying causes of disease, with a focus on conditions affecting the central nervous system and cardiovascular system.

Lexeo’s pipeline includes LX2006, an investigational gene therapy being developed for Friedreich’s ataxia cardiomyopathy, a potentially life-threatening cardiac complication of Friedreich’s ataxia.